Insights into the Association Between QSER1 and M2 Macrophages and Remarkable Malignancy Characteristics in Hepatocellular Carcinoma

References

• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–249. doi:10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Tang A, Hallouch O, Chernyak V, Kamaya A, Sirlin CB. Epidemiology of hepatocellular carcinoma: target population for surveillance and diagnosis. Abdom Radiol. 2018;43:13–25. doi:10.1007/s00261-017-1209-1
   PubMed Web of Science ®Google Scholar
• Kudo M. Management of hepatocellular carcinoma in Japan as a world-leading model. Liver Cancer. 2018;7:134–147. doi:10.1159/000484619
   PubMed Web of Science ®Google Scholar
• Llovet JM, Castet F, Heikenwalder M, et al. Immunotherapies for hepatocellular carcinoma. Nat Rev Clin Oncol. 2021. doi:10.1038/s41571-021-00573-2
   PubMed Web of Science ®Google Scholar
• Wang C, Cao Y, Yang C, Bernards R, Qin W. Exploring liver cancer biology through functional genetic screens. Nat Rev Gastroenterol Hepatol. 2021;18:690–704. doi:10.1038/s41575-021-00465-x
   PubMed Web of Science ®Google Scholar
• Lander ES, Linton LM, Birren B, et al. Initial sequencing and analysis of the human genome; 2001.
   Google Scholar
• Patel SJ, Sanjana NE, Kishton RJ, et al. Identification of essential genes for cancer immunotherapy. Nature. 2017;548:537–542. doi:10.1038/nature23477
   PubMed Web of Science ®Google Scholar
• Dufresne J, Bowden P, Thavarajah T, et al. The plasma peptides of ovarian cancer. Clin Proteomics. 2018;15:41. doi:10.1186/s12014-018-9215-z
   PubMed Web of Science ®Google Scholar
• Wang J, Sai K, Chen FR, Chen ZP. miR-181b modulates glioma cell sensitivity to temozolomide by targeting MEK1. Cancer Chemother Pharmacol. 2013;72:147–158. doi:10.1007/s00280-013-2180-3
   PubMed Web of Science ®Google Scholar
• Kim Y, Pierce CM, Robinson LA. Impact of viral presence in tumor on gene expression in non-small cell lung cancer. BMC Cancer. 2018;18:843. doi:10.1186/s12885-018-4748-0
   PubMed Web of Science ®Google Scholar
• Yi M, Li T, Qin S, et al. Identifying tumorigenesis and prognosis-related genes of lung adenocarcinoma: based on weighted gene coexpression network analysis. Biomed Res Int. 2020;2020:4169691. doi:10.1155/2020/4169691
   PubMed Web of Science ®Google Scholar
• Lee M, Kim K, Kim SY, et al. Genomic structures of dysplastic nodule and concurrent hepatocellular carcinoma. Hum Pathol. 2018;81:37–46. doi:10.1016/j.humpath.2018.06.026
   PubMed Web of Science ®Google Scholar
• Das T, Diamond DL, Yeh M, et al. Molecular signatures of recurrent hepatocellular carcinoma secondary to hepatitis C virus following liver transplantation. J Transplant. 2013;2013:878297. doi:10.1155/2013/878297
   PubMedGoogle Scholar
• Lian Q, Wang S, Zhang G, et al. HCCDB: a database of hepatocellular carcinoma expression atlas. Genomics Proteomics Bioinformatics. 2018;16:269–275. doi:10.1016/j.gpb.2018.07.003
   PubMed Web of Science ®Google Scholar
• Thul PJ, Lindskog C. The human protein atlas: a spatial map of the human proteome. Protein Sci. 2018;27:233–244. doi:10.1002/pro.3307
   PubMed Web of Science ®Google Scholar
• Chandrashekar DS, Bashel B, Balasubramanya SAH, et al. UALCAN: a portal for facilitating tumor subgroup gene expression and survival analyses. Neoplasia. 2017;19:649–658. doi:10.1016/j.neo.2017.05.002
   PubMed Web of Science ®Google Scholar
• Győrffy B. Survival analysis across the entire transcriptome identifies biomarkers with the highest prognostic power in breast cancer. Comput Struct Biotechnol J. 2021;19:4101–4109. doi:10.1016/j.csbj.2021.07.014
   PubMed Web of Science ®Google Scholar
• Gordon M, Lumley T, Gordon MM Package ‘forestplot’. Advanced forest plot using ‘grid’graphics The Comprehensive R Archive Network, Vienna; 2019.
   Google Scholar
• Liu C-J, Hu F-F, Xia M-X, Han L, Zhang Q, Guo A-Y. GSCALite: a web server for gene set cancer analysis. Bioinformatics. 2018;34:3771–3772. doi:10.1093/bioinformatics/bty411
   PubMed Web of Science ®Google Scholar
• Ju G, Zhou T, Zhang R, Pan X, Xue B, Miao S. DUSP12 regulates the tumorigenesis and prognosis of hepatocellular carcinoma. PeerJ. 2021;9:e11929. doi:10.7717/peerj.11929
   PubMed Web of Science ®Google Scholar
• Xu M, Zhu S, Xu R, Lin N. Identification of CELSR2 as a novel prognostic biomarker for hepatocellular carcinoma. BMC Cancer. 2020;20:313. doi:10.1186/s12885-020-06813-5
   PubMed Web of Science ®Google Scholar
• Li T, Fu J, Zeng Z, et al. TIMER2.0 for analysis of tumor-infiltrating immune cells. Nucleic Acids Res. 2020;48:W509–W514. doi:10.1093/nar/gkaa407
   PubMed Web of Science ®Google Scholar
• Jiang Y, Chen S, Li Q, et al. TANK-binding kinase 1 (TBK1) serves as a potential target for hepatocellular carcinoma by enhancing tumor immune infiltration. Front Immunol. 2021;12:612139. doi:10.3389/fimmu.2021.612139
   PubMed Web of Science ®Google Scholar
• Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017;45:W98–W102. doi:10.1093/nar/gkx247
   PubMed Web of Science ®Google Scholar
• Xu J, Liu C, Zhou L, et al. Distinctions between clinicopathological factors and prognosis of alpha-fetoprotein negative and positive hepatocellular carcinoma patients. Asian Pac J Cancer Prev. 2012;13:559–562. doi:10.7314/APJCP.2012.13.2.559
   PubMedGoogle Scholar
• Zhao T, Jia L, Li J, et al. Heterogeneities of site-specific N-glycosylation in HCC tumors with low and high AFP concentrations. Front Oncol. 2020;10:496. doi:10.3389/fonc.2020.00496
   PubMed Web of Science ®Google Scholar
• Liu Z, Pu Y, Bao Y, He S. Investigation of potential molecular biomarkers for diagnosis and prognosis of AFP-negative HCC. Int J Gen Med. 2021;14:4369–4380. doi:10.2147/IJGM.S323868
   PubMed Web of Science ®Google Scholar
• Yang C, Huang X, Li Y, Chen J, Lv Y, Dai S. Prognosis and personalized treatment prediction in TP53-mutant hepatocellular carcinoma: an in silico strategy towards precision oncology. Brief Bioinform. 2021;22:baa164.
   Web of Science ®Google Scholar
• Wang Q, Blank S, Fiel MI, et al. The severity of liver fibrosis influences the prognostic value of inflammation-based scores in hepatitis B-associated hepatocellular carcinoma. Ann Surg Oncol. 2015;22(Suppl 3):S1125–S1132. doi:10.1245/s10434-015-4598-9
   PubMed Web of Science ®Google Scholar
• Wang Q, Fiel MI, Blank S, et al. Impact of liver fibrosis on prognosis following liver resection for hepatitis B-associated hepatocellular carcinoma. Br J Cancer. 2013;109:573–581. doi:10.1038/bjc.2013.352
   PubMed Web of Science ®Google Scholar
• Everhart JE, Wright EC, Goodman ZD, et al. Prognostic value of Ishak fibrosis stage: findings from the hepatitis C antiviral long-term treatment against cirrhosis trial. Hepatology. 2010;51:585–594. doi:10.1002/hep.23315
   PubMed Web of Science ®Google Scholar
• Kinoshita A, Onoda H, Fushiya N, Koike K, Nishino H, Tajiri H. Staging systems for hepatocellular carcinoma: current status and future perspectives. World J Hepatol. 2015;7:406–424. doi:10.4254/wjh.v7.i3.406
   PubMed Web of Science ®Google Scholar
• Wang X, Tang H, Bowers JE, Feltus FA, Paterson AH. Extensive concerted evolution of rice paralogs and the road to regaining independence. Genetics. 2007;177:1753–1763.
   PubMed Web of Science ®Google Scholar
• Mao Y, Shen G, Su Z, Du J, Xu F, Yu Y. RAD21 inhibited transcription of tumor suppressor MIR4697HG and led to glioma tumorigenesis. Biomed Pharmacother. 2020;123:109759. doi:10.1016/j.biopha.2019.109759
   PubMed Web of Science ®Google Scholar
• Schütte K, Bornschein J, Malfertheiner P. Hepatocellular carcinoma–epidemiological trends and risk factors. Dig Dis. 2009;27:80–92. doi:10.1159/000218339
   PubMed Web of Science ®Google Scholar
• Villanueva A, Llovet JM. Mutational landscape of HCC—the end of the beginning. Nat Rev Clin Oncol. 2014;11:73–74. doi:10.1038/nrclinonc.2013.243
   PubMed Web of Science ®Google Scholar
• Kobayashi M, Ikeda K, Hosaka T, et al. Dysplastic nodules frequently develop into hepatocellular carcinoma in patients with chronic viral hepatitis and cirrhosis. Cancer. 2006;106:636–647. doi:10.1002/cncr.21607
   PubMed Web of Science ®Google Scholar
• Dixon G, Pan H, Yang D, et al. QSER1 protects DNA methylation valleys from de novo methylation. Science. 2021;373:372. doi:10.1126/science.373.6553.372
   PubMed Web of Science ®Google Scholar
• Costa Y, Ding J, Theunissen TW, et al. NANOG-dependent function of TET1 and TET2 in establishment of pluripotency. Nature. 2013;495:370–374. doi:10.1038/nature11925
   PubMed Web of Science ®Google Scholar
• Mishra L, Banker T, Murray J, et al. Liver stem cells and hepatocellular carcinoma. Hepatology. 2009;49:318–329. doi:10.1002/hep.22704
   PubMed Web of Science ®Google Scholar
• Ajani JA, Song S, Hochster HS, Steinberg IB. Cancer stem cells: the promise and the potential. Seminars in oncology; 2015; Elsevier; S3–S17.
   Google Scholar
• Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion. Science. 2011;331:1565–1570. doi:10.1126/science.1203486
   PubMed Web of Science ®Google Scholar
• Rabinovich GA, Gabrilovich D, Sotomayor EM. Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol. 2007;25:267–296. doi:10.1146/annurev.immunol.25.022106.141609
   PubMed Web of Science ®Google Scholar
• Sangro B, Sarobe P, Hervás-Stubbs S, Melero I. Advances in immunotherapy for hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2021;18:525–543. doi:10.1038/s41575-021-00438-0
   PubMed Web of Science ®Google Scholar
• Galindo CL, Skinner MA, Errami M, et al. Transcriptional profile of isoproterenol-induced cardiomyopathy and comparison to exercise-induced cardiac hypertrophy and human cardiac failure. BMC Physiol. 2009;9:23. doi:10.1186/1472-6793-9-23
   PubMedGoogle Scholar
• Eggert T, Wolter K, Ji J, et al. Distinct functions of senescence-associated immune responses in liver tumor surveillance and tumor progression. Cancer Cell. 2016;30:533–547. doi:10.1016/j.ccell.2016.09.003
   PubMed Web of Science ®Google Scholar
• Li X, Yao W, Yuan Y, et al. Targeting of tumour-infiltrating macrophages via CCL2/CCR2 signalling as a therapeutic strategy against hepatocellular carcinoma. Gut. 2017;66:157–167. doi:10.1136/gutjnl-2015-310514
   PubMed Web of Science ®Google Scholar
• Prieto J, Melero I, Sangro B. Immunological landscape and immunotherapy of hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2015;12:681–700. doi:10.1038/nrgastro.2015.173
   PubMed Web of Science ®Google Scholar
• Shi W, Zhang C, Ning Z, et al. CMTM8 as an LPA1-associated partner mediates lysophosphatidic acid-induced pancreatic cancer metastasis. Ann Transl Med. 2021;9:42. doi:10.21037/atm-20-1013
   PubMed Web of Science ®Google Scholar